Active substance
Calcitonin salmon
- SFDA 6
- US FDA 16
- US price lines 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MIACALCIC 100 IU-ML AMP | 100 IU/ml | Solution for infusion · Subcutaneous use | 5 Ampoule | SAR 118.90 | Biological · Prescription | NT Pharma International Company Limited | Valid |
| MIACALCIC AMP 50 IU-ML | 50 IU/ml | Solution for infusion · Subcutaneous use | 5 Ampoule | SAR 77.95 | Biological · Prescription | NT Pharma International Company Limited | Valid |
| CALCITEC 100 I.U NASAL SPRAY | 100 IU | Nasal spray · Nasal use | 1 Nasal Applicator | SAR 89.65 | Biological · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by regulatory authority · Not Marketed |
| CALCITEC 200 I.U NASAL SPRAY | 200 IU | Nasal spray · Nasal use | 1 Nasal Applicator | SAR 186.85 | Biological · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by regulatory authority · Not Marketed |
| CALCITEC 50 I.U NASAL SPRAY | 50 IU | Nasal spray · Nasal use | 1 Nasal Applicator | SAR 48.90 | Biological · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by regulatory authority · Not Marketed |
| MIACALCIC 200IU NASAL SPRAY | 200 IU | Nasal spray · Nasal use | 1 Nasal Applicator | SAR 270.75 | Biological · Prescription | NOVARTIS | Withdrawn by regulatory authority · Not Marketed |
Indications — CHI Daman Drug Formulary
MULTIPLE MYELOMA-HYPERCALCEMIA OF MALIGNANCY; PARATHYROID CANCER - HYPERCALCEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MIACALCIN | 200 IU/ML | injectable · injection | MYLAN IRELAND LTD | Prescription | 3 Jul 1986 |
| CALCITONIN-SALMON | 200 IU/SPRAY | spray, metered · nasal | APOTEX INC | Prescription | 17 Nov 2008 |
| CALCITONIN-SALMON | 200 IU/SPRAY | spray, metered · nasal | PH HEALTH | Prescription | 8 Jun 2009 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | CUSTOPHARM INC | Prescription | 14 May 2021 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | PH HEALTH | Prescription | 10 Nov 2021 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | DR REDDYS | Prescription | 11 Apr 2024 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | CIPLA | Prescription | 20 Sep 2024 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 5 Dec 2024 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | SAGENT | Prescription | 9 Jul 2025 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | AMNEAL | Prescription | 26 Sep 2025 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | ZYDUS PHARMS | Prescription | 4 Mar 2026 |
| CALCIMAR | 200 IU/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | SANOFI AVENTIS US | Discontinued | 17 Apr 1978 |
| MIACALCIN | 100 IU/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | MYLAN IRELAND LTD | Discontinued | 3 Jul 1986 |
| MIACALCIN | 200 IU/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | spray, metered · nasal | SAPTALIS PHARMS | Discontinued | 17 Aug 1995 |
| CALCITONIN-SALMON | 200 IU/ML | injectable · injection | IGI LABS INC | Discontinued | |
| CALCIMAR | 400 IU/VIAL | injectable · injection | SANOFI AVENTIS US | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CALCITONIN-SALMON 200 UNIT SPR | $13.10383 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 12 Sep 2017 MIACALCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations - US FDA 11 Sep 2017 MIACALCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.